Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2013-11-29 Declaration of Voting R…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly states the total number of voting rights as of the end of November 2013 (60,414,220). This content directly relates to the official results or status of shareholder voting rights, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a full AGM presentation (AGM-R), nor is it a general earnings release or a comprehensive report like a 10-K or IR.
2013-11-29 English
DGAP-DD: STADA Arzneimittel AG deutsch
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "DGAP-DD: STADA Arzneimittel AG deutsch Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG Directors’-Dealings-Mitteilung". It details a transaction (Kauf/Purchase) by a member of the management board ('Funktion: Geschäftsführendes Organ') involving company shares, including the date, price, and quantity. This directly corresponds to the definition of Director's Dealing.
2013-11-19 German
Q3 Report 2013
Earnings Release Classification · 99% confidence The document text contains detailed financial tables summarizing key figures for '9 months 2013' compared to '9 months 2012', including Group sales, operating profit, EBITDA, and net income. It also includes a section titled 'CONSOLIDATED INTERIM MANAGEMENT REPORT' discussing performance over the first nine months of 2013 and providing an outlook. The explicit mention of 'interim report' and the focus on a nine-month period strongly indicate a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Annual Report (10-K) because it covers only nine months, nor is it just an Earnings Release (ER) as it contains a detailed management report and extensive financial breakdowns. 9M 2013
2013-11-15 English
Declaration of Voting Results & Voting Rights Announcements 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' ('Stimmrechtsmitteilung' in German) and details changes in shareholder voting rights percentages crossing specific thresholds (3%) as reported under German securities law (§ 21 Abs. 1 WpHG). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA). The document is short and appears to be the announcement itself, not a comprehensive report.
2013-11-14 German
STADA records satisfactory development in the first nine months of 2013 - sales growth of 8 percent - adjusted EBITDA margin at 19.8 percent
Earnings Release Classification · 100% confidence The document is a 'Press release' detailing the 'satisfactory development in the first nine months of 2013' for STADA Arzneimittel AG, including key financial figures like Group sales, EBITDA, and net income compared to the previous year (1-9/2012). It provides a comprehensive summary of financial performance for a period shorter than a full year (nine months) and includes management commentary and outlook. This structure aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), a brief Earnings Release (ER), or a Call Transcript (CT). Since it contains detailed financial figures for a specific interim period, it is classified as IR. 9M 2013
2013-11-13 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is extremely short (1297 characters) and explicitly titled 'Total Voting Rights Announcement'. It states the total number of voting rights as of October 31, 2013. This type of announcement, which reports on the total number of shares carrying voting rights, is a specific regulatory disclosure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit, as it deals directly with voting rights disclosure, even though it is a total count rather than specific results from a meeting.
2013-10-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.